ALKS vs. MDGL, FOLD, IONS, GERN, AGIO, LGND, DVAX, PCRX, MNKD, and IRWD
Should you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Madrigal Pharmaceuticals (MDGL), Amicus Therapeutics (FOLD), Ionis Pharmaceuticals (IONS), Geron (GERN), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND), Dynavax Technologies (DVAX), Pacira BioSciences (PCRX), MannKind (MNKD), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.
Alkermes (NASDAQ:ALKS) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk.
Alkermes received 236 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 70.72% of users gave Alkermes an outperform vote while only 68.60% of users gave Madrigal Pharmaceuticals an outperform vote.
Alkermes has a net margin of 25.17% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Alkermes' return on equity of 20.31% beat Madrigal Pharmaceuticals' return on equity.
Alkermes has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.33, suggesting that its share price is 133% less volatile than the S&P 500.
Alkermes currently has a consensus target price of $36.78, indicating a potential upside of 53.05%. Madrigal Pharmaceuticals has a consensus target price of $345.09, indicating a potential upside of 46.94%. Given Alkermes' higher probable upside, equities research analysts plainly believe Alkermes is more favorable than Madrigal Pharmaceuticals.
In the previous week, Alkermes had 1 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 7 mentions for Alkermes and 6 mentions for Madrigal Pharmaceuticals. Alkermes' average media sentiment score of 1.10 beat Madrigal Pharmaceuticals' score of 0.65 indicating that Alkermes is being referred to more favorably in the media.
95.2% of Alkermes shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 4.9% of Alkermes shares are owned by company insiders. Comparatively, 23.9% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Alkermes has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
Summary
Alkermes beats Madrigal Pharmaceuticals on 13 of the 17 factors compared between the two stocks.
Get Alkermes News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alkermes Competitors List
Related Companies and Tools
